Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

MAR002 Phase 1 results showed deep, durable IGF-1 suppression and pharmacokinetic properties that may permit dosing as infrequently as once every two weeks. That could compare favorably with daily subcutaneous injections required by the current standard of care; the article provides no further trial results or market reaction.